Scarica il programma in formato PDF

LUCEM DEFEATING LUNG CANCER SHARING THE EXPERIENCE

LUNG CANCER EUROPEAN MEETING (LUCE-M )

Wednesday, July 5 ^th , 2017

Università degli Studi di Milano Bicocca, Medicina e Chirurgia, U8, Aula 5 Via Cadore, 48, Monza - Italy

Provider CME, Scientific and Organizational Secretariat

With the unrestricted grant of: With the presence of:

Secondo le finalità

della Rete Oncologica Regionale

LUCEM DEFEATING LUNG CANCER SHARING THE EXPERIENCE LUNG CANCER EUROPEAN MEETING (LUCE-M )

CME ID 2157-196058

The International Congress “LUCEM DEFEATING LUNG CANCER SHARING THE EXPERIENCE LUNG CANCER EUROPEAN MEETING (LUCE-M)”, have been awarded 6,9 Credits for the following professions: Medical surgeon (all disciplines): Biologist, Nurse. The event is credited to a maximum of 100 participants. The credits will be provided with a complete participation in scientific work and learning exam with at least 75%

of correct answers.

Inscription

Membership is free and entitles you to participation in Congress, Conference kit, certificate of attendance, coffee-break and lunch buffet.

To enroll, send your personal data (name, surname, telephone number, e-mail), to the following address email: [email protected], or at the following fax number: 02 93661995. For organizational purposes, entries must be received by July 4th, 2017.

CHAIRMAN

Diego Luigi Cortinovis

Medical Oncologist, San Gerardo Hospital, Monza, Italy

FACULTY

Claudia M. R. Bareggi: Medical Oncology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy Anna Bettini: Medical Oncology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy

Paolo Bidoli: S.C. Medical Oncology Unit, ASST Monza, Italy

Stefania Canova: Oncologia Medica, Ospedale San Gerardo di Monza, Italy

Jesus Corral Jaime: Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain Marina Garassino: Thoracic medical oncology, Istituto Nazionale dei Tumori, Milan, Italy

Matteo Giaj Levra: Unité d’Oncologie et Oncologie Thoracique, Centre hospitalo-universitaire de Grenoble - Hôpital Michallon, France Ignacio Gil-Bazo: Clínica Universidad de Navarra - Center for Applied Medical Research, Pamplona, Spain

Nicolas Girard: Respiratory Medicine Service, Hôpital Louis Pradel, Hospices Civils de Lyon, France

Vanesa Gregorc: Department of Oncology IRCCS Scientific Institute Ospedale San Raffaele (University Hospital), Milan, Italy Niki Karachaliou: Translational Research Group in Pangaea Biotech SA, Barcelona

Marcos Pantarotto: Medical Oncology, Hospital Da Luz, Lisboa, Portugal

Antonio Passaro: Division of Thoracic Oncology, European Institute of Oncology, IEO, Milan, Italy Patrick Pauwels: Clinic of pathological anatomy, UZA Antwerp University Hospital, Edegem, Belgium

Christian Rolfo: Clinical Trial Management Program Oncology Department University Hospital Antwerp UZA, Edegem, Belgium Luca Toschi: Humanitas Cancer Center, IRCCS U.O. di Oncologia ed Ematologia, Milan, Italy

Ania Wrona: Department of Oncology and Radiotherapy - Medical University of Gdansk, Poland

WITH THE PATRONAGE OF:

Provider CME, Scientific and Organizational Secretariat Medica Editoria e Diffusione Scientifica srl

Corso Venezia, 37 – 20121 Milano Tel. +39 02 76281337 – Fax 02 93661995 E-mail: [email protected]

Rete Oncologica Lombarda Secondo le finalità della Rete Oncologica Regionale – ROL

SCIENTIFIC RATIONALE

The therapeutic pathways in managing non-small cell lung cancer are now extremely complex and articulated and start from a basic biomolecular evaluation. This evalua- tion aims to provide the clinician with the tools needed for precision medicine.

Through these determinations, a therapeutic strategy can be developed that is diffe- rent for each tumor subtype, but that makes the concept of chronic neoplastic lung disease ever more within reach.

Targeted therapies, immunotherapies and antiangiogenic therapies become valuable- allies in the fight against this type of cancer. The availability and applicability in clinical practice can create long-term survivors following this diagnosis.

These aspects are further corroborated by the clinical research and networks. The in- ternational collaboration between clinicians and investment in biomolecular platforms are the key to truly effective and powerful research needed to ensure optimal targeted therapy for each tumor.

AGENDA

LUCEM DEFEATING LUNG CANCER SHARING THE EXPERIENCE

LUNG CANCER EUROPEAN MEETING (LUCE-M )

10.00 Welcome and Introduction Diego Cortinovis

First session: the breakthroughs in clinical practice Diego Cortinovis, Luca Toschi 10.15 Second line perspectives in nsq-NSCLC: Is it a real second chance for patients? Ignacio Gil-Bazo

10.45 The corner discussion: panelists All

11.00 Releasing the brakes of the immune system: what is the impact of pd1/pdl1 abs in clinical practice?

Jesus Corral Jaime

11.30 The corner discussion: panelists All

11.45 SCC management in 2016: what is the gap between trials and clinical practice? Nicolas Girard

12.15 Discussion corner: panelists All

12.30 Critical aspects: i have just ten minutes Marina Garassino

12.40 Lunch break

Second session: special populations Stefania Canova,

Claudia M.R. Bareggi

13.40 EGFR MUT+VE PTS: we don’t miss any opportunity Christian Rolfo

14.00 Discussion corner: panelists All All

14.10 ALK +VE: we don’t miss any opportunity Patrick Pauwels

14.20 Discussion corner: panelists All All

14.30 The “other” OMA’s: practical management at a glance Niki Karachaliou

14.50 Discussion corner: panelists All All

15.00 Critical aspects: i have just ten minutes…… Paolo Bidoli

15.10 Coffee break

Third session: the wind blows throughout Europe Anna Bettini, Antonio Passaro 15.30 The opportunity to care for lung cancer patients in Europe: not only chemotherapy Marcos Pantarotto 16.00 How Europe may contribute to clinical research on lung cancer?

(networking and biobanking) EORTC?

Matteo Giaj Levra 16.30 Access to therapies in lung cancer: is there more than “one Europe”? Ania Wrona

17.10 I have just ten minutes…….. Vanesa Gregorc

17.10 Closing Remarks Diego Cortinovis